84539-22-0

Basic information

• Product Name: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE
• Synonyms: 4-(5-BROMO-PYRIMIDIN-2-YL)-MORPHOLINE;5-BROMO-2-(4-MORPHOLINO)-PYRIMIDINE;5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE;2-Morpholino-5-bromopyrimidine
• CAS NO: 84539-22-0
• Molecular Formula: C₈H₁₀BrN₃O
• Molecular Weight: 244.09
• Product Categories: Organohalides;Pyrimidine
• Mol File: 84539-22-0.mol

Chemical Properties

• Melting Point: 125.0-127.7 °C
• Boiling Point: 382.815oC at 760 mmHg
• Flash Point: 185.32oC
• Appearance: White to off-white/Crystalline Powder
• Density: 1.571g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C
• PKA: 3.23±0.42(Predicted)
• CAS DataBase Reference: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(84539-22-0)
• EPA Substance Registry System: 5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE(84539-22-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 84539-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-MORPHOLIN-1-YL-PYRIMIDINE is used as a key intermediate in the synthesis of carbamimidoylcarbamate derivatives, which are novel vascular adhesion protein-1 (VAP-1) inhibitors. VAP-1 is an enzyme involved in the inflammatory process and has been implicated in various diseases, including diabetes, atherosclerosis, and asthma. By inhibiting VAP-1, these carbamimidoylcarbamate derivatives have the potential to treat these conditions and improve patient outcomes.

InChI:InChI=1/C8H10BrN3O/c9-7-5-10-8(11-6-7)12-1-3-13-4-2-12/h5-6H,1-4H2

Upstream product

• 57356-66-8 4-(pyrimidin-2-yl)morpholine 
• 110-91-8 morpholine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 37828-58-3 lithium morpholide 
• 183438-24-6 5-bromo-2-iodopyrimidine 

Downstream Products

• 926009-39-4 4-{5-[5-(4-chlorophenyl)-6-iodopyrimidin-4-ylethynyl]pyrimidin-2-yl}morpholine 
• 870521-33-8 [2-(morpholin-4-yl)pyrimidin-5-yl]boronic acid 
• 957198-30-0 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]morpholine 
• 842974-69-0 2-(morpholin-4-yl)pyrimidine-5-carbaldehyde 

Relevant articles and documents

Room-Temperature Amination of Chloroheteroarenes in Water by a Recyclable Copper(II)-Phosphaadamantanium Sulfonate System

Buchwald-Hartwig amination of chloroheteroarenes has been a challenging synthetic process, with very few protocols promoting this important transformation at ambient temperature. The current report discusses about an efficient copper-based catalytic system (Cu/PTABS) for the amination of chloroheteroarenes at ambient temperature in water as the sole reaction solvent, a combination that is first to be reported. A wide variety of chloroheteroarenes could be coupled efficiently with primary and secondary amines as well as selected amino acid esters under mild reaction conditions. Catalytic efficiency of the developed protocol also promotes late-stage functionalization of active pharmaceutical ingredients (APIs) such as antibiotics (floxacins) and anticancer drugs. The catalytic system also performs efficiently at a very low concentration of 0.0001 mol % (TON = 980,000) and can be recycled 12 times without any appreciable loss in activity. Theoretical calculations reveal that the π-acceptor ability of the ligand PTABS is the main reason for the appreciably high reactivity of the catalytic system. Preliminary characterization of the catalytic species in the reaction was carried out using UV-VIS and ESR spectroscopy, providing evidence for the Cu(II) oxidation state.

INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION

The compounds of Formula I, II, and III along with their stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof are described in the present disclosure. The said compounds restore immune activation in case of infections or a disease associated with an HIV infection in a subject in need thereof.

LDHA ACTIVITY INHIBITORS

The invention provides compounds of formula (I), stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof: (I) wherein A1 to A6 and R1 to R4 are as defined herein. Such compounds are suit

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2

The present invention directs to a compound represented by formula (I).

HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.

Synthesis of 5-(het)aryl- and 4,5-di(het)aryl-2-(thio)morpholinopyrimidines from 2-chloropyrimidine via SN H and cross-coupling reactions

It has been shown that various combinations of nucleophilic aromatic substitution of hydrogen (SN H), SN ipso and the microwave-assisted Suzuki cross-coupling reactions are a versatile method for the synthesis o

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor δ agonists

The discovery, synthesis, and optimization of compound 1 from a high-throughput screening hit to highly potent and selective peroxisome proliferator-activated receptor δ (PPARδ) agonists are reported. The synthesis and structure-activity relationship in this series are described in detail. On the basis of a general schematic PPAR pharmacophore model, scaffold 1 was divided into headgroup, linker, and tailgroup and successively optimized for PPAR activation using in vitro PPAR transactivation assays. A (2-methylphenoxy)acetic acid headgroup, a flexible linker, and a five-membered heteroaromatic center ring with two hydrophobic aryl substituents were required for efficient and selective PPARδ activation. The fine-tuning of these aryl substituents led to an array of highly potent and selective compounds such as compound 38c, displaying an excellent pharmacokinetic profile in mouse. In an in vivo acute dosing model, selected members of this array were shown to induce the expression of pyruvate dehydrogenase kinase-4 (PDK4) and uncoupling protein-3 (UCP3), genes that are known to be involved in energy homeostasis and regulated by PPARδ in skeletal muscle.

Oxidative amination of cuprated pyrimidine and purine derivatives

Using regioselective cuprations (via magnesiations), various primary, secondary and tertiary aminated pyrimidine and purine derivatives were prepared by the oxidative coupling of lithium amidocuprates using chloranil. DNA and RNA units such as aminated uracil or thymine, and adenine, as well as a CDK inhibitor, purvalanol A, were all obtained under mild conditions and satisfactory yields.